Monitor shareholder vote on merger proposals and Nasdaq listing approval. CYCN stock may trade based on merger arbitrage dynamics; if merger fails, CYCN likely faces liquidation risk. CVRs provide potential but highly uncertain upside from legacy asset monetization.
Price Chart
Executive Summary
Cyclerion Therapeutics files S-4/A for reverse merger with Korsana Biosciences. Current CYCN shareholders will own ~1.5% of the combined company, while Korsana holders (including a $380M pre-closing financing) will own ~98.5%. The combined company will focus on Korsana's preclinical Alzheimer's candidate KRSA-028. CYCN's existing cash of $3.2M is insufficient to continue as a going concern without the merger. Shareholders receive contingent value rights (CVRs) for legacy assets, which may be valueless.
Key Facts
- CYCN shareholders to own ~1.5% of combined company on fully-diluted basis vs. ~98.5% for Korsana holders
- Korsana raised ~$380M in pre-closing PIPE from top-tier healthcare investors
- CYCN has substantial doubt as a going concern with only $3.2M cash as of Dec 2025
- Combined company to focus on Korsana's preclinical anti-amyloid antibody KRSA-028 for Alzheimer's
- Shareholders receive CVRs for legacy assets with no guarantee of payment
- Reverse stock split required to meet Nasdaq listing minimum bid price
- Merger expected to close in Q3 2026; conditions include shareholder and Nasdaq approval
Financial Impact
Massive dilution for CYCN shareholders from ~100% to ~1.5% ownership; no financial figures provided for combined company revenue or earnings
Risk Factors
- Merger may not close if shareholder or Nasdaq conditions are not met
- CYCN shareholders face near-total dilution of economic interest
- CVRs may expire worthless if legacy assets are not monetized
- Combined company is preclinical with no approved products and requires significant additional capital
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-4/A Filing (Primary) | 0001193125-26-263731 |
| Document: d111069dex1028.htm | 0001193125-26-263731 |
| Document: d111069dex1034.htm | 0001193125-26-263731 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 20d ago | SC 13G/A | — | awaiting T+5 | — | — |
Sep 11, 2026 6w ago | 8-K | $3.47 | awaiting T+5 | — | — |
Sep 10, 2026 6w ago | 3 | $3.47 | awaiting T+5 | — | — |
Aug 27, 2026 8w ago | 8-K | $3.99 $4.96 | ▲ +24.31% | ▲ +24.04% | — |
Aug 10, 2026 11w ago | 425 | $3.57 $4.12 | ▲ +15.41% | ▲ +15.81% | — |
Aug 3, 2026 12w ago | 425 | $3.51 $3.57 | ▲ +1.71% | ▲ +1.81% | — |
Jul 27, 2026 13w ago | EFFECT | $3.50 $3.44 | ▼ −1.71% | ▼ −2.79% | — |
Jul 10, 2026 15w ago | 425 | $3.82 $3.64 | ▼ −4.71% | ▼ −3.93% | — |
Jun 9, 2026 20w ago | S-4/A | $3.09 $3.18 | ▼ −2.91% | ▲ +0.52% | — |
Apr 30, 2026 25w ago | 10-K/A | $3.31 $3.24 | ▼ −2.11% | ▼ −3.84% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers